Remote Liver Ischemic Preconditioning Attenuates Myocardial Ischemia/reperfusion Injury in Streptozotocin-induced Diabetic Rats

Xinhao Liu  
  Sichuan University West China Hospital

Hui Chen  
  Sichuan University West China Hospital

Zhibing Yan  
  Sichuan University West China Hospital

Lei Du  
  Sichuan University West China Hospital

Dou Huang  
  Sichuan University West China Hospital

WeiDong Gao  
  Johns Hopkins University School of Medicine

Zhaoyang Hu (zyhu@hotmail.com)  
  Sichuan University West China Hospital  https://orcid.org/0000-0003-3642-9610

Original investigation

Keywords: Remote liver ischemic preconditioning, Diabetes, Myocardial ischemia/reperfusion injury, Infarction, Cardioprotection, GSK-3β/STAT5 signaling pathway

DOI: https://doi.org/10.21203/rs.3.rs-38824/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
**Abstract**

**BACKGROUND:** Diabetes mellitus (DM) exhibits a higher sensitivity to myocardial ischemia/reperfusion (I/R) injury and may compromise the effectiveness of cardioprotective interventions, including ischemic preconditioning. We previously found that liver ischemic preconditioning (RLIPC) could limit infarct size post I/R in normal rat hearts and further exerted anti-arrhythmic effects in diabetic or non-diabetic rats after myocardial I/R, however, little is known regarding the effect of RLIPC on infarct-sparing in diabetic hearts. In this study, we evaluated the protective effects of RLIPC on I/R injury in streptozotocin (STZ)-induced type 1 diabetic rats.

**METHODS:** Type 1 diabetes mellitus was induced by one-time intraperitoneal injection of streptozotocin in Sprague–Dawley rats. Rats were exposed to 45 min of left anterior descendin (LAD) coronary artery occlusion, followed by 3 h of reperfusion. For liver ischemic preconditioning, four cycles of 5 min of liver I/R stimuli were performed before LAD occlusion. the cardioprotective effect of RLIPC was determined in diabetic rats.

**RESULTS:** Compared to non-RLIPC treated DM rats, RLIPC treatment significantly reduced infarct size in diabetic hearts post I/R. RLIPC also improved cardiac functions including LVESP, LVEDP, dp/dtmax, and -dp/dtmax. In addition, RLIPC could largely preserved cardiac morphology by reducing the pathological score post I/R in diabetic hearts. Finally, western blotting analysis showed that RLIPC stimulated phosphorylation of ventricular GSK-3β and STAT-5, which are key components of RISK and SAFE signaling pathways.

**Background**

Cardiovascular disease is the most predominant cause of morbidity and mortality in patients with diabetes mellitus (DM). Abundant evidence has clearly demonstrated that patients with type 1 or type 2 diabetes are at high risk for ischemic heart disease and the mortality rate of acute myocardial infarction is dramatically increased in diabetic patients versus non-diabetic patients [1]. Myocardial ischemia reperfusion (I/R) injury is a significant complication of reperfusion therapy for myocardial infarction. Clinical and epidemiological studies indicate that diabetic hearts are more prone to I/R injury [2], that is, diabetes is associated with larger infarcts and worse outcomes. Therefore, new strategies to limit infarction in clinical settings is of great importance.

Ischemic preconditioning, which is induced by episodes of controlled ischemia-reperfusion, was first demonstrated to have protective effect on myocardium against I/R injury in dog [3]. Later, it was shown that this type of myocardial protection against I/R injury can be induced by imposing episodes of controlled ischemia-reperfusion in other remote organs, i.e. remote ischemic preconditioning [4]. For example, limb [5] or liver ischemic stimuli [6], applied prior to coronary artery occlusion, was demonstrated to be associated with reduced infarct size. A number of randomized clinical trials were also conducted and showed the beneficial effect of remote ischemia preconditioning [7, 8]. However, despite the
overwhelming data indicating the effectiveness of preconditioning-induced cardioprotection, there is concern that the infarct-sparing effect of ischemic conditioning may be abolished or compromised in the diabetic heart[9]. Interestingly, we found that brief ischemic preconditioning of liver reduced the occurrences of myocardial I/R-provoked ventricular arrhythmia in diabetic heart[10]. However, whether this remote liver ischemic preconditioning (RLIPC) could protect diabetic hearts against infarction is incompletely understood.

The exact mechanism underlying the cardioprotective effect of remote ischemic conditioning is unclear. Activation of reperfusion injury salvage kinase (RISK) pathway, or the survivor activating factor enhancement (SAFE) pathways can be involved in ischemic preconditioning and postconditioning[11, 12]. We previously reported that RLIPC activated RISK pathway post I/R, specifically, increased ERK1/2[10], AKT[13], and GSK-3β[6] protein phosphorylation. Meanwhile, the inhibition of STAT3, the vital signal molecule in SAFE pathway, abolished the protective action of liver preconditioning[12]. However, whether RLIPC may alter RISK and SAFE pathway in diabetic hearts is unknown.

Therefore, using a left anterior descending coronary artery (LAD) occlusion-induced myocardial I/R rat model, we evaluated the therapeutic efficacy of liver ischemic preconditioning in acute streptozotocin-induced diabetic hearts and reported an underlying possible molecular mechanism for its protective effect.

**Methods**

**Animals**

The protocols of animal experiments were approved by the Institutional Animal Care and Use Committee of Sichuan University (2015035A). Male rats (Sprague Dawley, 200-250 g body weight, 8 weeks old) were purchased from Dashuo Experimental Animal Research Center (Chengdu, China). The rats were housed in specific-pathogen free environment with a circadian rhythm of 12 h light/12 h darkness and free access to food and water.

**Rat model of type 1 diabetes**

Rats received one-time intraperitoneal injection of streptozotocin (STZ, 50 mg/kg) (STZ,Sigma Chemical Co., St. Louis, MO, USA) to develop type 1 diabetes[14]. STZ was dissolved in 0.1M citrate buffer (pH 4.5). One Touch Ultra Glucose meter was used to measure blood glucose 7 days following STZ injection (Roche, USA). Diabetic rats were defined as rats with glucose levels equal to or more than 20 mmol/L. Rats that did not meet the criteria were excluded.

**Experimental Protocol**

The experimental protocols were delineated in **Figure 1**. Rats were randomly assigned as follows: (1) sham group (sham) without diabetes: hepatic portal and left coronary artery were isolated with suture placed underneath but not tightened; (2) control group without diabetes (CON): rats were subjected to left
anterior descending coronary artery (LAD) occlusion. No hepatic intervention was implemented. (3) CON with RLIPC: rats were subjected to LAD occlusion with pretreatment of hepatic ischemia; (4) sham group with diabetes (DM-sham), hepatic portal artery and LAD were isolated with suture placed underneath but not tightened in diabetic rats; (5) control group with diabetes (DM-CON): diabetic rats had LAD occlusion. No hepatic intervention was implemented; (6) DM-CON with remote liver ischemic preconditioning treatment group (DM-RLIPC): diabetic rats had LAD occlusion with pretreatment of hepatic ischemia. In a parallel study (experiment 2), blood samples were obtained at the end of the experiment for the test of serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) to rule out the possibility that liver stimuli might affect liver function.

**Surgical procedure**

Rats were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneal). Anesthesia was monitored by the loss of the corneal reflex. Ligation of LAD was performed as previously reported [6, 15]. In brief, after the rat was anesthetized, it was ventilated with a rodent ventilator throughout the experiment (Taimeng, Chengdu, China). After thoracotomy, LAD was exposed and the 6-0 silk was placed under LAD (Ethicon, Somerville, NJ, USA). LAD was occluded for 45 min followed by 180 min of reperfusion. Exhibition of epicardial cyanosis and dyskinesia in the heart was observed as evidence of successful occlusion of LAD. Upon reperfusion, epicardial hyperemic response was seen in LAD region of the heart. Hemodynamic parameters were recorded during the entire experiment (Taimeng, Chengdu, China). Remote liver ischemic preconditioning was done by four cycles of clamping hepatic artery, portal vein and venous trunk for 5 min followed by 5 min reperfusion. At the end of the reperfusion, the rats were euthanized with an overdose of sodium pentobarbital (200 mg/kg, i.p.). LAD was then untied and left ventricle (LV) was filled with 1% Evans blue (Sigma Chemical Co., St. Louis, MO, USA) to show the ischemic area at risk (AAR). Tissue samples in the AAR were then taken and stored in -80°C freezer for later protein phosphorylation analysis.

**Hemodynamic analyses**

After stabilization, a 20-G catheter (Spacelabs Medical, Inc., Redmond, WA, USA) was inserted into the LV via the right carotid artery. The catheter was then connected to a pressure transducer (Biolap 420F, Taimeng, Chengdu, China) for hemodynamic measurements such as left ventricular end diastolic pressure (LVEDP), left ventricular systolic pressure (LVSP), and maximum rate of increase/decrease in left ventricular pressure (±dP/dtmax).

**Serum tests**

Blood samples were taken at the end of the experiment and the serum was obtained by centrifugation (1000 g, 10 min, 4°C). The serum was then frozen at -20°C until further analysis. Levels of AST and ALT were measured by an automatic BS-120 biochemical analyzer (Mindray, Shenzhen, China).

**Determination of myocardial infarct size**
Hearts were briefly frozen and then cut into transverse slices (2 mm thick) and myocardial infarct size was determined by triphenyltertrazolium chloride (TTC) staining. The heart slices were incubated with 1% TTC (Sigma Chemical Co., St. Louis, MO, USA) in 0.1 M phosphate buffer (pH 7.4) for 20 min at 37°C. Tissues were then fixed in 10% formalin at room temperature overnight. Infarcted myocardial tissues within AAR were unstained (white) and non-infarcted areas were stained red. They were carefully separated and weighed. Infarct size was presented as a percentage of the AAR.

**Heart tissue collection**

At the end of the experiment, AAR regions were identified and were immersed in 10% formaldehyde solution, followed by dehydration in a separated group of hearts. These hearts were embedded in paraffin and sliced into 5μm thick consecutive sections parallel to the atrioventricular groove. Heart sections were mounted on glass slides prior to being stained with hematoxylin and eosin (H&E).

**Pathological Evaluation**

Myocardial pathological scores were determined based on a modified numerical scoring system[15] according to: (1) the severity of myocardial damage (i.e. myofibril degeneration, oedema, or subendocardial haemorrhage) with 0 indicating normal, 1 mild, 2 moderate and 3 significant; (2) the distribution of myocardial damage with 0 indicating normal, 1 focal, 2 multifocal and 3 diffuse. A mean score was calculated for each heart in a double-blinded manner.

**Western blotting**

Heart tissue samples were homogenized in lysis buffer consisting of 150 mMNaCl, 50 mMTris-HCl(pH7.4), 0.25% sodium deoxycholate, 1% NP-40, 1 mM EDTA, and phosphatase and protease inhibitor cocktails (Sigma Chemical Co., St. Louis, MO, USA). The homogenates were then centrifuged at 4°C for 10 minutes at 10,000x g. Protein concentration was determined using BCA assay kit (Pierce, Rockford, IL, USA). Sample were separated on 12% SDS-PAGE gel (15μg/well). The protein bands were then transferred onto nitrocellulose membranes (VWR, Batavia, IL, USA). The membranes were then blocked for 1h and incubated at 4°C overnight with the following primary antibodies: phosphorylated extracellular signal-regulated kinase1/2 (ERK1/2) (Thr202/Tyr204), total ERK1/2, phosphorylated glycogen synthase kinase-3β (Ser9) (p-GSK-3β Ser9), total -GSK-3β Ser9, phospho-Akt (Ser473, p-Akt), total Akt, phosphorylated STAT3 (Tyr705) (p-STAT3), and total STAT3, phosphorylated STAT5 (Tyr694) (p-STAT5), and total STAT5 (all: rabbit, 1:1000, from Cell Signaling Technology, Danvers, MA, USA). We used horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG as secondary antibody and target bands were detected using a chemoiluminescence ECL (Millipore, Billerica, MA, USA) and were visualized using Amersham Imager 600 (GE healthcare, Little Chalfont, UK). The images were then analyzed with ImageJ Data Acquisition Software (National Institutes of Health, Bethesda, MD, USA).

**Statistical Analysis**
All data were presented as mean ± standard error of the mean (SEM). Statistical analyses were performed using SPSS 13.0 software for Windows (SPSS Inc., Chicago, IL, USA) or Graphpad Prism 5 software (GraphPad Software, Inc. La Jolla, CA, USA). Two-way repeated-measures ANOVA was used to analyze hemodynamics data. One-way ANOVA followed by Newman-Keuls test was used for multiple group comparison. Statistical significance was set as P < 0.05 (two-tailed)

**Results**

**Confirmed phenotype of DM rats**

Our experimental protocol successfully induced diabetes (DM) in the rats by single intraperitoneal administering of STZ. After 7 days, DM rats showed a 30% decrease in body weight (all p<0.001, Figure 2A) and hyperglycemia with doubled or tripled blood glucose level (all p<0.001, Figure 2B) when compared to rats without STZ injection in sham, CON and RLIPC group.

**Remote liver ischemic preconditioning reduces myocardial infarct size**

We first investigated if RLIPC caused liver injury by measuring serum levels of AST and ALT. We found that there was no significant difference in serum levels of AST (Figure 3A) and ALT (Figure 3B) between RLIPC and non-RLIPC, control rats (all p > 0.05). This result suggested that RLIPC did not cause liver injury. Infarct size of diabetic rats increased approximately 24% when compared with normal rats after myocardial I/R as a result of LAD occlusion and re-opening (61.74%±1.82% vs. 49.58%±2.78%, p<0.001) (Figure 4B). This suggests that diabetic state aggravates the I/R injury caused by LAD ligation. Interestingly, we found that RLIPC resulted in a 20% reduction of cardiac infarct size when compared to non-RLIPC group in both normal (39.91%±1.66% in RLIPC vs. 49.58%±2.78% in CON, p<0.01) and DM rats (50.70%±1.59% in DM-RLIPC vs. 61.74%±1.82% in DM-CON, p<0.01) (Figure 4A, B), suggesting RLIPC effectively limited the infarct size in diabetic or non-diabetic rats. Meanwhile, we did not see any difference in the ratio of the AAR to the LV among groups, indicating similar areas affected by LAD ligation (Figure 4B, p>0.05). We also evaluated the cardiac injury using the pathological scoring system. Consistent with TTC staining results, RLIPC significantly reduced pathological score when compared to non-RLIPC control group in both normal rats and DM rats (Figure 5).

**Hemodynamic measurements**

The time course of hemodynamics was shown in Table 1. Systemic hemodynamics were comparable among each group under baseline conditions (p>0.05). LVSP (p=0.002), dP/dt$_{max}$ (p=0.001), LVEDP (p=0.003) and -dP/dt$_{max}$ (p=0.001) were significantly different among CON, RLIPC, DM-CON and DM-RLIPC group during the 3h of reperfusion. There were significant interactions between groups and the time course for LVSP (p=0.011), dP/dt$_{max}$ (p=0.028), LVEDP (p=0.003) and -dP/dt$_{max}$ (p=0.001). Recovery of cardiac function was significantly better in RLIPC group in both normal and DM rats when compared to CON group in terms of the above-mentioned parameters (p<0.01 for all).
ERK phosphorylation is reported to be associated with cardiac pathophysiological process like myocardial infarction. We found that LAD ligation significantly increased ERK1/2 phosphorylation by 3-4 folds in both normal (p<0.001) and DM rats (p<0.001) (Figure 6A). However, RLIPC did not alter the pattern of increased ERK phosphorylation caused by LAD ligation in both normal and DM rats (Figure 6A). This suggested that ERK phosphorylation was not associated with RLIPC-induced cardioprotection in diabetic hearts. We previously found GSK-3β phosphorylation was associated with cardiac protection offered by liver ischemic conditioning[6]. As expected, we again showed that RLIPC significantly increased GSK-3β phosphorylation by 2-3 folds when compared to CON rats (p<0.001), and the same effect was also observed in DM rats (p<0.001) (Figure 6B). This suggested increased GSK phosphorylation caused by RLIPC was not affected by diabetic state. AKT signaling pathway was reported to be associated with cardiac injury caused by myocardial infarction. Consistently, we also found that AKT phosphorylation increased by 50% in the CON when compared to sham ones (p<0.05). However, RLIPC could not further increase the phosphorylation levels of AKT in both normal and DM rats when compared with their corresponding non-RLIPC controls(Figure 6C).

The signal transducers and activators of transcription (STAT) functions as regulators of cellular stress. We next investigated if STAT signaling was involved in the cardiac protection from RLIPC. We found that STAT3 phosphorylation was significantly increased by 6-7 folds in the CON and DM-CON groups compared to sham (p<0.001) and DM-sham (p<0.001) groups, respectively. RLIPC did not alter the expression pattern of STAT3 phosphorylation induced by LAD ligation (Figure 6D), suggesting STAT3 signaling pathway is not associated with RLIPC-induced cardioprotection. Surprisingly, although STAT5 phosphorylation was similar between rats with LAD ligation and sham surgery, we found that RLIPC increased STAT5 phosphorylation by 2 folds compared to non-LAD ligation rats in both normal (p<0.001) and DM rats (p<0.001), indicating that STAT5 signaling plays a role in the cardioprotective effect of RLIPC in both non-diabetic and diabetic rat hearts (Figure 6E).

**Discussion**

The present data suggests that pretreatment with liver ischemic preconditioning prior to a 45 min LAD occlusion and a subsequent 3 h reperfusion reduced myocardial injury in STZ-induced diabetic rat hearts, as shown by reduced infarct size and decreased pathological score. To our knowledge, this is the first study reporting the results of using RLIPC in a diabetic myocardial I/R model. Our data demonstrate that increased GSK-3β and STAT-5 phosphorylation may be associated with RLIPC treatment in diabetic hearts.

**Diabetes and myocardial protection**

DM is a common metabolic disorder, characterized by hyperglycemia, hyperlipidemia, and hypoinsulimia. Patients with DM have increased risk of coronary artery disease and myocardial infarction [24]. Furthermore, diabetic patients exhibit a higher sensitivity to myocardial reperfusion-induced injury[16], as
such, it is more difficult for diabetic patients to recover from heart attack after pharmacological or mechanical reperfusion strategies including fibrinolytic therapy or percutaneous transluminal coronary intervention (PCI)\[17]. Our study revealed that myocardial damage caused by reperfusion injury was more severe in diabetic rats than that in non-diabetic rats. This suggests that hyperglycemia may have a more adverse impact on cardiomyocytes in response to ischemia and reperfusion stimuli. Therefore, effective therapeutic approaches and novel targets are required to rescue reperfusion-injured myocardium in diabetic state.

Since remote ischemic conditioning was found beneficial to the recovery after myocardial infarction, multiple clinical trials have conducted to evaluate the effect of remote limb ischemic conditioning in patients with myocardial infarction. Botker and colleagues showed that remote limb ischemic conditioning applied during myocardial infarction period before hospital admission increased salvaged area of myocardium [7]. Other clinical studies have also confirmed the effect of limb ischemic conditioning during cardiac surgery, elective PCI, and acute myocardial infarction[4]. Additionally, liver is the biggest metabolic organ in the body that remote ischemic conditioning can be applied. Compared with limb ischemic conditioning, which has been studied intensively, the effect of liver ischemic conditioning was largely unknown. We and others have reported that RLIPC reduced infarct area in normal hearts in vivo[10] or ex vivo[18]. More recently, our laboratory demonstrated the existence of anti-arrhythmic effect of RLIPC post myocardial I/R in diabetic heart[14]. In the current study, we tested the efficacy of RLIPC in STZ-injected rats whose beta pancreatic cells were destroyed leading to type I diabetes phenotype. To the best of our knowledge, RLIPC-induced infarct-sparing effects has never been tested in type 1 diabetes models. The current results demonstrated that pretreatment of liver ischemic stimuli before sustained myocardial ischemia limits infarction post-I/R in diabetic rats. However, our results contrast with reports concerning that efficacy of ischemic conditioning could be attenuated, or may even completely lost in diabetes[19-21]. This discrepancy may be explained by the possible interactions between anti-diabetic medication and remote ischemic conditioning, different protocols of designs of conducting ischemia cycles and observing different primary outcomes, as well as differences in animal species.

**RISK/SAFE pathway in diabetes**

Although efforts have been made trying to find new signaling targets contributing to the remote ischemic preconditioning-induced anti-infarction against myocardial I/R injury, little is known about the potential role of RLIPC in cardioprotection in diabetic hearts. Reperfusion injury salvage kinase (RISK) pathway, first described by Yellon et al[11] has been demonstrated to be involved in remote ischemic conditioning in multiple studies[22]. RISK pathway includes two major kinases cascades: the p42/p44 extracellular signal-regulated kinases (ERK1/2) and kinase B (AKT), all of those are pro-survival protein kinases, responsible for cell proliferation, transcription and survival[11]. The RISK pathway can be activated in response to stress such as ischemia-reperfusion, initiating phosphorylation of a wide array of intracellular targets, resulting in modification of protein synthesis. The failure of cardioprotection by ischemic conditioning in diabetes has largely been attributed to the impaired activation of signaling molecules in
RISK pathway[9]. We therefore evaluated whether RLIPC-induced infarct limitation in diabetic heart is associated with the RISK signaling kinases. It has been shown that either ischemic conditioning or pharmaceuticals could induce ERK1/2 or AKT phosphorylation, thus ultimately reduced myocardial infarct size[23, 24]. We previously found that RLIPC protected hearts against sudden cardiac death via activation of ERK1/2 pathway[10]. Meanwhile, we also observed increased phospho- AKT levels in the brain of RLIPC rats compared to controls[13]. However, in the current study, we found that pretreatment with liver I/R stimulus prior to LAD occlusion did not enhance ERK1/2 or AKT phosphorylation in diabetic or non-diabetic hearts. It seems that the infarction sparing effect of RLIPC against myocardial I/R injury is independent of these two signaling cascades. However, Glycogen synthase kinase-3β (GSK-3β), the vital component of the RISK pathway, is an essential regulator of survival in cardiac myocytes, thus is involved in the pathogenesis of myocardial I/R injury. The phosphorylation within the amino-terminal domain of GSK-3β at Ser9, results in the inhibition of GSK-3 kinase activity[25] and inactivation therefore, is cardioprotective[26]. Prior studies provides evidence that ischemic conditioning can stimulate GSK-3β phosphorylation[27]. We found in our previous study that RLIPC caused GSK-3β phosphorylation in normal hearts post I/R[6], our current study extends these findings by showing that RLIPC exerted cardioprotection via increasing phosphorylation of ventricular GSK-3β in diabetic hearts compared with non-RLIPC treated diabetic hearts post I/R. Our data are consistent with previous studies showing that pretreatment with GSK-3β inhibitors prior to myocardial ischemia produced cardioprotection in diabetic hearts[28].

The survivor activating factor enhancement (SAFE) pathways, another cell survival pathway independent of the RISK pathway has been shown to be associated with I/R injury[29, 30]. It involves the activation of signal transducer and activator of transcription 3 (STAT3) and 5 (STAT5). Previous studies have shown that STAT3 or STAT5 phosphorylation at reperfusion was increased with remote preconditioning in various animal models[12, 31]. Accordingly, the protective effect of preconditioning can be blocked with the administration of STAT inhibitors[32]. We previously showed that increased phospho-STAT3 and STAT5 levels were found in the RLIPC-treated rat lungs and the administration of STAT inhibitor could effectively block the pulmonary protection offered by RLIPC[12]. However, it contrasts with our current findings that STAT5 phosphorylation, not STAT3, played a role in the protective effect of RLIPC in both normal and diabetic rats. This suggested that activation of SAFE pathway may be organ specific. Taken together, RLIPC induced infarction sparing effect in diabetic and non-diabetic hearts may share a similar mechanism involving activation of GSK-3β and STAT-5 signaling pathways.

**Limitations**

Our study has several limitations. First, animal model of type 1 diabetes(streptozotocin induced) was used in the current study, rather than a high-fat diet induced type of diabetes (type II), the latter may better mimic human metabolite signature, characterized by insulin resistance and hyperinsulinemia. Thus, it is not clear if RLIPC may exert cardioprotection against I/R injury on type 2 diabetes. Second, streptozotocin was used for induction of type 1 diabetic animal model, however, the chemical has been reported to be toxic at other organs of the body, including liver[33], therefore, it remains unknown whether this chemical
can affect the efficiency of liver preconditioning stimuli. Third, our protocol had fixed preconditioning
cycle of liver ischemia and reperfusion stimuli, therefore, it is not certain if the number of ischemic cycles
and duration of ischemic period have dose-response relationship in terms of the cardioprotective effect of
RLIPC. Fourth, diabetes may desensitize, remodel or even shift other signaling molecules. We only
determine several signaling molecules in RISK and SAFE pathway, it is possible that other molecules and
signaling cascades may also be involved in the cardioprotective effect of RLIPC. In addition, our study did
not investigate the interaction between pathways, such as the crosstalk between RISK and SAFE
pathway. Therefore, future attention will be focused on functional studies so as to indentify the
relationship between the cardioprotective effect and those altered molecules. Finally, our animal model is
limited in that only significant hyperglycemia was present. Nevertheless, given the importance of
hyperglycemia in aggravating I/R injury in the heart, our results from this model do provide relevant
understanding on RLIPC mediated myocardial protection during ischemia and reperfusion.

Conclusions

Liver ischemic preconditioning exerts strong cardioprotective effects in diabetic heart post I/R injury, as
evidenced by decreased infarction size, improved cardiac function and alleviated cardiac damage. This
RLIPC-induced cardioprotection is mediated by the activation of GSK-3\(\beta\) and STAT-5 signaling pathways.

Abbreviations

DM: diabetes mellitus; RLIPC: remote liver ischemic preconditioning; STZ: streptozotocin; I/R: ischemia
reperfusion; LVSP: left ventricular systolic pressure; LVEDP: left ventricular end-diastolic pressure;
\(\pm dP/dt_{max}\): maximum rate of increase/decrease in left ventricular pressure; ERK: extracellular signal-
regulated kinase; GSK-3\(\beta\): glycogen synthase kinase-3\(\beta\); RISK: reperfusion injury salvage kinase pathway;
SAFE: survivor activating factor enhancement pathways; LAD: left anterior descending coronary artery;
STAT3: signal transducer and activator of transcription 3; STAT5: signal transducer and activator of
transcription 5;

Declarations

Acknowledgements

Not applicable.

Ethics approval and consent to participate

All the experimental protocols and procedures were approved by the Institutional Animal Care and Use
Committee of Sichuan University Sichuan, China, (Approval Number: 2015035A). All rats in the current
study were treated in accordance with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health (NIH Publication 8th edition, 2011).
Consent for publication

Not applicable

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ZH designed the research; XL, HC, ZY, DH and ZH conducted the experiments; XL, HC, ZY, LD, DH, WDG and ZH analyzed the data; XL and ZH wrote the manuscript; WDG revised and edited the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by Sichuan University West China Hospital Setup Funds (to ZH).

References

1. Jacoby RM, Nesto RW: Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992, 20(3):736-744.

2. Lejay A, Fang F, John R, Van JA, Barr M, Thaveau F, Chakfe N, Geny B, Scholey JW: Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol 2016, 91:11-22.

3. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74(5):1124-1136.

4. Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D: Remote ischemic conditioning. J Am Coll Cardiol 2015, 65(2):177-195.

5. Schmidt MR, Smerup M, Konstantinov IE, Shimizu M, Li J, Cheung M, White PA, Kristiansen SB, Sorensen K, Dzavik V et al: Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol 2007, 292(4):H1883-1890.

6. Yang S, Abbott GW, Gao WD, Liu J, Luo C, Hu Z: Involvement of glycogen synthase kinase-3beta in liver ischemic conditioning induced cardioprotection against myocardial ischemia and reperfusion injury in rats. J Appl Physiol (1985) 2017, 122(5):1095-1105.
7. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S et al: Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010, 375(9716):727-734.

8. White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, Tehrani S, Flett AS, Meier P, Ariti C et al: Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2015, 8(1 Pt B):178-188.

9. Wider J, Przyklenk K: Ischemic conditioning: the challenge of protecting the diabetic heart. Cardiovasc Diagn Ther 2014, 4(5):383-396.

10. Hu Z, Hu S, Yang S, Chen M, Zhang P, Liu J, Abbott GW: Remote Liver Ischemic Preconditioning Protects against Sudden Cardiac Death via an ERK/GSK-3beta-Dependent Mechanism. PLoS One 2016, 11(10):e0165123.

11. Hausenloy DJ, Yellon DM: New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004, 61(3):448-460.

12. Luo N, Liu J, Chen Y, Li H, Hu Z, Abbott GW: Remote ischemic preconditioning STAT3-dependently ameliorates pulmonary ischemia/reperfusion injury. PLoS One 2018, 13(5):e0196186.

13. Yang G, Yang Y, Li Y, Hu Z: Remote liver ischaemic preconditioning protects rat brain against cerebral ischaemia-reperfusion injury by activation of an AKT-dependent pathway. Exp Physiol 2020, 105(5):852-863.

14. Hu Z, Chen M, Zhang P, Liu J, Abbott GW: Remote ischemic preconditioning differentially attenuates post-ischemic cardiac arrhythmia in streptozotocin-induced diabetic versus nondiabetic rats. Cardiovasc Diabetol 2017, 16(1):57.

15. Hu Z, Crump SM, Zhang P, Abbott GW: Kcne2 deletion attenuates acute post-ischaemia/reperfusion myocardial infarction. Cardiovasc Res 2016, 110(2):227-237.

16. Li H, Liu Z, Wang J, Wong GT, Cheung CW, Zhang L, Chen C, Xia Z, Irwin MG: Susceptibility to myocardial ischemia reperfusion injury at early stage of type 1 diabetes in rats. Cardiovasc Diabetol 2013, 12:133.

17. Nystrom T, Sartipy U, Franzen S, Eliasson B, Gudbjornsdottir S, Miftaraj M, Lagerqvist B, Svensson AM, Holzmann MJ: PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease. J Am Coll Cardiol 2017, 70(12):1441-1451.

18. Noorbakhsh MF, Arab HA, Kazerani HR: Liver ischemia preconditions the heart against ischemia-reperfusion arrhythmias. Iran J Basic Med Sci 2015, 18(1):80-88.
19. Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM: **Preconditioning the diabetic human myocardium.** *J Cell Mol Med* 2010, **14**(6B):1740-1746.

20. Whittington HJ, Harding I, Stephenson CI, Bell R, Hausenloy DJ, Mocanu MM, Yellon DM: **Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling.** *Cardiovasc Res* 2013, **99**(4):694-704.

21. Han Z, Cao J, Song D, Tian L, Chen K, Wang Y, Gao L, Yin Z, Fan Y, Wang C: **Autophagy is involved in the cardioprotection effect of remote limb ischemic postconditioning on myocardial ischemia/reperfusion injury in normal mice, but not diabetic mice.** *PLoS One* 2014, **9**(1):e86838.

22. Hausenloy DJ, Tsang A, Yellon DM: **The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning.** *Trends Cardiovasc Med* 2005, **15**(2):69-75.

23. Hu Z, Liu J, Zhou L, Tian X, Abbott GW: **AKT and ERK1/2 activation via remote ischemic preconditioning prevents Kcne2-dependent sudden cardiac death.** *Physiol Rep* 2019, **7**(3):e13957.

24. Heinen NM, Putz VE, Gorgens JI, Huhn R, Gruber Y, Barthuber C, Preckel B, Pannen BH, Bauer I: **Cardioprotection by remote ischemic preconditioning exhibits a signaling pattern different from local ischemic preconditioning.** *Shock* 2011, **36**(1):45-53.

25. Forde JE, Dale TC: **Glycogen synthase kinase 3: a key regulator of cellular fate.** *Cell Mol Life Sci* 2007, **64**(15):1930-1944.

26. Tamareille S, Mateus V, Ghaboura N, Jeanneteau J, Croue A, Henrion D, Furber A, Prunier F: **RISK and SAFE signaling pathway interactions in remote limb ischemic perconditioning in combination with local ischemic postconditioning.** *Basic Res Cardiol* 2011, **106**(6):1329-1339.

27. Rose BA, Force T, Wang Y: **Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.** *Physiol Rev* 2010, **90**(4):1507-1546.

28. Yadav HN, Singh M, Sharma PL: **Involvement of GSK-3beta in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart.** *Mol Cell Biochem* 2010, **343**(1-2):75-81.

29. Bolli R, Stein AB, Guo Y, Wang OL, Rokosh G, Dawn B, Molkentin JD, Sanganalmath SK, Zhu Y, Xuan YT: **A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning.** *J Mol Cell Cardiol* 2011, **50**(4):589-597.

30. Lecour S: **Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway?** *J Mol Cell Cardiol* 2009, **47**(1):32-40.

31. Kleinbongard P, Skyschally A, Gent S, Pesch M, Heusch G: **STAT3 as a common signal of ischemic conditioning: a lesson on "rigor and reproducibility" in preclinical studies on cardioprotection.** *Basic Res*
32. Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, Siddiqui MA, Das DK: Role of STAT3 in ischemic preconditioning. *J Mol Cell Cardiol* 2001, 33(11):1929-1936.

33. Lee JH, Yang SH, Oh JM, Lee MG: Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. *J Pharm Pharmacol* 2010, 62(1):1-23.

**Tables**

Table 1 The effect of RLIPC on hemodynamics
| Variable       | Baseline     | Reperfusion |
|---------------|--------------|-------------|
|                |              | 1h          | 2h          | 3h          |
| LVSP (mmHg)   |              |             |             |             |
| CON           | 135.3±10.1   | 104.1±11.2*** | 98.8±5.2*** | 85.9±11.6*** |
| RIPC          | 137.5±4.0    | 110.8±6.3**† | 111.5±10.6***#† | 104.3±6.7***##† |
| DM-CON        | 139.8±13.9   | 101.7±7.2*** | 96.0±4.7*** | 91.0±9.5***  |
| DM-RLIPC      | 136.7±8.0    | 110.0±4.8***†| 112.2±6.8***##†| 105.5±5.8***##† |
| LVEDP (mmHg)  |              |             |             |             |
| CON           | -5.3±1.9     | 1.0±0.3***  | 3.0±0.8***  | 5.7±1.6***   |
| RLIPC         | -5.1±2.0     | -1.2±0.9**#†| 0.7±0.2***##† | 2.2±0.9***##††† |
| DM-CON        | -6.3±1.8     | 1.4±0.8***  | 3.3±2.1***  | 5.4±0.8***   |
| DM-RLIPC      | -5.6±1.9     | -2.7±1.6*#† | -0.2±0.2**#† | 2.9±1.1***##†† |
| dp/dtmax (mmHg/ms) |    |             |             |             |
| CON           | 5.1±0.6      | 2.9±0.6***  | 2.3±0.9***  | 1.6±0.6***   |
| RLIPC         | 5.3±1.1      | 3.7±1.0*    | 3.5±0.7**#† | 3.4±0.6***##††† |
| DM-CON        | 5.6±0.7      | 2.7±0.7***  | 2.4±1.0***  | 1.5±0.6***   |
| DM-RLIPC      | 5.4±1.0      | 3.8±1.1*    | 3.9±0.8***##† | 3.2±0.3***##††† |
| -dp/dtmax (mmHg/ms) | |             |             |             |
| CON           | -4.9±0.5     | -2.8±0.5*** | -2.2±0.3*** | -1.4±0.7***  |
| RLIPC         | -5.2±1.0     | -4.1±1.2***#†| -3.3±0.9**#† | -3.1±0.7***##††† |
| DM-CON        | -4.8±0.8     | -2.2±0.9*** | -2.1±0.9*** | -1.3±0.6***  |
| DM-RLIPC      | -5.3±0.9     | -4.0±0.4***##†† | -3.5±0.8***##† | -3.4±0.5***##††† |

Data are expressed as mean±SEM. **CON:** LAD occlusion only, **RLIPC:** remote liver ischemic preconditioning, **DM:** STZ-induced diabetes. LVSP=left ventricular systolic pressure, LVEDP=left ventricular end-diastolic pressure; ±dP/dtmax=maximum rate of increase/decrease in left ventricular pressure. n=6 in each group. *P<0.05, **P<0.01, ***P<0.001 versus baseline, #P<0.05, ##P<0.01, ###P<0.001 versus CON, †P<0.05, ††P<0.01 versus DM-CON.
Flowsheet of experimental protocol

Red block: four cycles of liver ischemic stimuli.
Black block: duration of left anterior descending (LAD) coronary occlusion.
Grey block: duration of reperfusion.
Sham: sham-operated surgery,
CON: LAD occlusion only,
RLIPC: remote liver ischemic preconditioning,
DM: STZ-induced diabetes.

**Figure 1**

Flowchart of experimental protocol
Red block: four cycles of liver ischemic stimuli.
Black block: duration of left anterior descending (LAD) coronary occlusion.
Grey block: duration of reperfusion.
Sham: sham-operated surgery,
CON: LAD occlusion only,
RLIPC: remote liver ischemic preconditioning,
DM: STZ-induced diabetes.
Figure 2

Body weight and plasma glucose after STZ treatment (A) body weight (n=7-10); (B) plasma glucose (n=6-10). Sham, sham surgery; CON, LAD ligation; RLIPC, remote liver ischemic pre-conditioning; DM: STZ-induced diabetes. Data presented as mean±SEM. ***p<0.001 compared with normal rats (by one-way ANOVA).

Figure 3

Remote ischemic preconditioning did not cause liver injury (A) plasma AST (n=5-6); (B) plasma ALT (n=5-6). Sham, sham surgery; RLIPC, remote liver ischemic preconditioning; DM: diabetic rats. Data presented as mean±SEM. NS: non-significant between groups (p>0.05, by one-way ANOVA).
Figure 4

Remote ischemic preconditioning alleviated myocardial infarction (A) Representative sections of triphenyltetrazolium chloride (TTC)-stained heart subjected to 45min myocardial ischemia followed by 3hrs of reperfusion. Sham, sham surgery; CON, LAD ligation; RLIPC, remote liver ischemic preconditioning; DM: diabetic rats. (B) Quantification of myocardial infarct size expressed as a percentage of leftventricular (LV) area at risk (AAR) (top) and AAR expressed as a percentage of LV area (bottom). Data were presented as mean±SEM; n = 6-7 each group. **p<0.01 and ***p<0.001 compared with CON; ##p<0.01 and ###p<0.001 compared with RLIPC; and † † p<0.01 compared with DM-CON (by one-way ANOVA).
Figure 5

Effect of RLIPC on morphological changes post-myocardial ischemia/reperfusion (A) Representative (of n = 4 rats/group) H&E stained heart sections are shown. Heart histopathology scores were determined under a light microscope; Panel (a) scale bars: 100 μm; panel (b) scale bars, 20 μm. Sham, sham surgery; CON, LAD ligation; RLIPC, remote liver ischemic preconditioning; DM: diabetic rats. Data were presented as mean±SEM; *p<0.05 and ***p<0.001 compared with CON; #p<0.05 and ###p<0.001 compared with RLIPC; and ††p<0.01 compared with DM-CON (by one-way ANOVA).
Figure 6
RLIPC stimulated GSK-3β and p-STAT-5 phosphorylation in both non-diabetic and diabetic rats. Representative Western blots (left) and quantification (right) of p-ERK1/2 (A), p-GSK-3β (B), p-AKT (C), p-STAT-3 (D) and p-STAT-5 (E) protein band densities (normalized to total protein, respectively) in sham, CON and RLIPC group in both normal and Diabetic rats. Sham, sham surgery; CON, LAD ligation; RLIPC, remote liver ischemic preconditioning; D: diabetic rats. (n=3-5), data were presented as mean±SEM. *p<0.05 and ***p<0.001 compared with Sham. #p<0.05 and ###p<0.001 compared with DM-sham. †††p<0.001 compared with CON. ‡‡‡p<0.001 compared with DM-CON. (by one-way ANOVA).